Sample PLR Article Directory Jersey: 2016

Thursday, September 29, 2016

Spanil

Spanil may be available in the countries listed below.

Ingredient matches for Spanil

Scopolamine

Scopolamine is reported as an ingredient of Spanil in the following countries:

Bangladesh

International Drug Name Search

Acanya

Acanya is a brand name of benzoyl peroxide/clindamycin topical, approved by the FDA in the following formulation(s):

ACANYA (benzoyl peroxide; clindamycin phosphate - gel; topical)

Manufacturer: DOW PHARM SCI

Approval date: October 23, 2008

Strength(s): 2.5%;1.2% ^[RLD]

Has a generic version of Acanya been approved?

No. There is currently no therapeutically equivalent version of Acanya available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Acanya. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Compositions of clindamycin and benzoyl peroxide for acne treatment
Patent 5,733,886
Issued: March 31, 1998
Inventor(s): Baroody; Lloyd J. & Dow; Gordon J. & Dow; Debra A. & Lathrop; Robert
Assignee(s): Baroody; Lloyd J.
Dow; Gordon J.
Compositions suitable for the treatment of acne by topical application comprise clindamycin and benzoyl peroxide. Kits for preparing the compositions include a solution of clindamycin in a first container and a gel suspension of benzoyl peroxide in a second container. Each component is stored at a pH which promotes stability, and the combination of the two components provides a final composition having a pH which promotes stability and enhances viscosity.
Patent expiration dates:
- March 31, 2015
  ✓
  Patent use: TREATMENT OF ACNE
  ✓
  Drug product

Compositions for the treatment of acne containing clindamycin and benzoyl peroxide
Patent 6,117,843
Issued: September 12, 2000
Inventor(s): Baroody; Lloyd J. & Dow; Gordon J. & Dow; Debra A. & Lathrop; Robert
Assignee(s): Baroody; Lloyd J.
Dow; Gordon J.
A pharmaceutical composition containing clindamycin and benzoyl peroxide is disclosed for the treatment of acne. The composition is stable for several months when stored at room temperature. Methods of preparing and of using the composition are disclosed.
Patent expiration dates:
- February 18, 2012
  ✓
  Drug product

Wednesday, September 28, 2016

Sinemet

SINEMET (carbidopa; levodopa - tablet; oral)

Manufacturer: MERCK SHARP DOHME

Approved Prior to Jan 1, 1982

Strength(s): 10MG;100MG ^[AB], 25MG;100MG ^[AB], 25MG;250MG ^[RLD]^[AB]

Has a generic version of Sinemet been approved?

Yes. The following products are equivalent to Sinemet:

CARBIDOPA AND LEVODOPA (carbidopa; levodopa tablet; oral)

Manufacturer: ACTAVIS ELIZABETH

Approval date: September 3, 1993

Strength(s): 10MG;100MG ^[AB], 25MG;100MG ^[AB], 25MG;250MG ^[AB]

Manufacturer: APOTEX INC

Approval date: June 2, 2008

Strength(s): 10MG;100MG ^[AB], 25MG;100MG ^[AB], 25MG;250MG ^[AB]

Manufacturer: MYLAN

Approval date: September 28, 2009

Strength(s): 10MG;100MG ^[AB], 25MG;100MG ^[AB], 25MG;250MG ^[AB]

Manufacturer: SUN PHARM INDS

Approval date: October 28, 2008

Strength(s): 10MG;100MG ^[AB], 25MG;100MG ^[AB], 25MG;250MG ^[AB]

Manufacturer: TEVA

Approval date: August 28, 1992

Strength(s): 10MG;100MG ^[AB], 25MG;100MG ^[AB], 25MG;250MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Sinemet. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Sinemet.

Has a generic version of Sinemet CR been approved?

Yes. The following products are equivalent to Sinemet CR:

CARBIDOPA AND LEVODOPA (carbidopa; levodopa tablet, extended release; oral)

Manufacturer: APOTEX

Approval date: June 16, 2004

Strength(s): 25MG;100MG ^[AB], 50MG;200MG ^[AB]

Manufacturer: IMPAX LABS

Approval date: May 14, 2004

Strength(s): 25MG;100MG ^[AB], 50MG;200MG ^[AB]

Manufacturer: MYLAN

Approval date: September 30, 1999

Strength(s): 50MG;200MG ^[AB]

Manufacturer: MYLAN

Approval date: April 21, 2000

Strength(s): 25MG;100MG ^[AB]

Manufacturer: SUN PHARM INDS

Approval date: August 23, 2007

Strength(s): 25MG;100MG ^[AB], 50MG;200MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Sinemet CR. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Sinemet CR.

Has a generic version of Solodyn been approved?

A generic version of Solodyn has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Solodyn and have been approved by the FDA:

minocycline hydrochloride tablet, extended release; oral

Manufacturer: BARR

Approval date: March 17, 2009

Strength(s): EQ 135MG BASE ^[AB], EQ 45MG BASE ^[AB], EQ 90MG BASE ^[AB]

Manufacturer: IMPAX LABS INC

Approval date: February 3, 2009

Strength(s): EQ 135MG BASE ^[AB], EQ 45MG BASE ^[AB], EQ 90MG BASE ^[AB]

Manufacturer: LUPIN LTD

Approval date: November 30, 2011

Strength(s): EQ 135MG BASE ^[AB], EQ 45MG BASE ^[AB], EQ 90MG BASE ^[AB]

Manufacturer: MATRIX LABS LTD

Approval date: July 20, 2010

Strength(s): EQ 135MG BASE ^[AB], EQ 45MG BASE ^[AB], EQ 90MG BASE ^[AB]

Manufacturer: SANDOZ

Approval date: August 13, 2009

Strength(s): EQ 135MG BASE ^[AB], EQ 45MG BASE ^[AB], EQ 90MG BASE ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Solodyn. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Method for the treatment of acne
Patent 5,908,838
Issued: June 1, 1999
Inventor(s): Gans; Eugene H.
Assignee(s): Medics Pharmaceutical Corporation
A method for the treatment of acne is provided which results in the reduction of vestibular side effects following administration of oral tetracycline antibiotics.
Patent expiration dates:
- February 19, 2018
  ✓
  Patent use: TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS

Minocycline oral dosage forms for the treatment of acne
Patent 7,541,347
Issued: June 2, 2009
Inventor(s): Wortzman; Mitchell & Plott; R. Todd & Bhatia; Kuljit & Patel; Bhiku
Assignee(s): Medicis Pharmaceutical Coropration
Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne.
Patent expiration dates:
- April 2, 2027
  ✓
  Patent use: TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS

Minocycline oral dosage forms for the treatment of acne
Patent 7,544,373
Issued: June 9, 2009
Inventor(s): Wortzman; Mitchell & Plott; R. Todd & Bhatia; Kuljit & Patel; Bhiku
Assignee(s): Medicis Pharmaceutical Corporation
Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne.
Patent expiration dates:
- April 2, 2027
  ✓
  Drug product

Minocycline oral dosage forms for the treatment of acne
Patent 7,790,705
Issued: September 7, 2010
Inventor(s): Wortzman; Mitchell & Plott; R. Todd & Bhatia; Kuljit & Patel; Bhiku
Assignee(s): Medicis Pharmaceutical Corporation
Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne.
Patent expiration dates:
- June 24, 2025
  ✓
  Patent use: TREATMENT OF ACNE

Method for the treatment of acne
Patent 7,919,483
Issued: April 5, 2011
Inventor(s): Wortzman; Mitchell & Plott; R. Todd & Bhatia; Kuljit & Patel; Bhiku
Assignee(s): Medicis Pharmaceutical Corporation
A method for treatment of acne with tetracyclines is provided. A lower sustained dose and no loading dose is employed, with an optional once-a-day dosing regimen.
Patent expiration dates:
- March 7, 2027
  ✓
  Patent use: TREATMENT OF ACNE

Ingredient matches for Procid

Omeprazole

Omeprazole is reported as an ingredient of Procid in the following countries:

India

Probenecid

Probenecid is reported as an ingredient of Procid in the following countries:

Taiwan

International Drug Name Search

Optison

Generic Name: perflutren protein type a microsphere (Intravenous route)

per-FLOO-tren PROE-teen type A MYE-kroe-sfeers

Intravenous route(Suspension)

Serious cardiopulmonary reactions, including fatalities, have occurred during or following perflutren-containing microsphere administration. Monitor vital signs, electrocardiography, and cutaneous oxygen saturation during and for at least 30 minutes after perflutren-containing microsphere administration in patients with pulmonary hypertension or unstable cardiopulmonary conditions, and have resuscitation equipment and trained personnel available .

Commonly used brand name(s)

In the U.S.

Optison

Available Dosage Forms:

Suspension

Therapeutic Class: Diagnostic Agent, Cardiac Function

Uses For Optison

The albumin microspheres sonicated preparation is an ultrasound contrast agent. Ultrasound contrast agents are used to help provide a clear picture during ultrasound. Ultrasound is a special kind of diagnostic procedure. It uses high-frequency sound waves to create images or “pictures” of certain areas inside the body. The sound waves produced by the ultrasound equipment can be reflected (bounced off) by different parts of the body, like for example, the heart. As the sound waves return they are electronically converted into images on a television screen. Unlike x-rays, ultrasound does not involve ionizing radiation.

The albumin microspheres sonicated preparation contains very small gas-filled albumin microspheres that reflect the sound waves and help create a better picture. The albumin microspheres sonicated preparation is given by injection into a vein before ultrasound to help diagnose problems of the heart.

The albumin microspheres sonicated preparation is to be given only by or under the direct supervision of a doctor with specialized training in ultrasound procedures.

Before Using Optison

In deciding to use a diagnostic test, any risks of the test must be weighed against the good it will do. This is a decision you and your doctor will make. Also, other things may affect test results. For this test, the following should be considered:

Allergies

Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.

Pediatric

Studies on this agent have been done only in adult patients, and there is no specific information comparing use of albumin microspheres sonicated in children with use in other age groups.

Geriatric

Many medicines have not been studied specifically in older people. Therefore, it may not be known whether they work exactly the same way they do in younger adults. There is no specific information comparing use of albumin microspheres sonicated in the elderly with use in other age groups.

Pregnancy

	Pregnancy Category	Explanation
All Trimesters	C	Animal studies have shown an adverse effect and there are no adequate studies in pregnant women OR no animal studies have been conducted and there are no adequate studies in pregnant women.

Breast Feeding

There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.

Interactions with Medicines

Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. Tell your healthcare professional if you are taking any other prescription or nonprescription (over-the-counter [OTC]) medicine.

Interactions with Food/Tobacco/Alcohol

Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.

Proper Use of Optison

Your doctor may have special instructions for you in preparation for your test. If you do not understand the instructions you receive or if you have not received such instructions, check with your doctor in advance.

Dosing

The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.

The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.

Precautions While Using Optison

There are no special precautions to observe after having this test.

Optison Side Effects

Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur:

Less common or rare

Chest pain; difficulty breathing or shortness of breath; itching; skin rash

Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Dizziness; flushing of skin or sensation of warmth; headache; nausea and/or vomiting

Less common

Changes in taste; dryness of mouth; fatigue; pain at injection site; weakness

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

See also: Optison side effects (in more detail)

The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.

The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.

More Optison resources

Optison Side Effects (in more detail)
Optison Use in Pregnancy & Breastfeeding
Optison Drug Interactions
Optison Support Group
0 Reviews · Be the first to review/rate this drug

Optison MedFacts Consumer Leaflet (Wolters Kluwer)

Optison Prescribing Information (FDA)

Perflutren Professional Patient Advice (Wolters Kluwer)

Definity MedFacts Consumer Leaflet (Wolters Kluwer)

Definity Prescribing Information (FDA)

Biotonus

Biotonus may be available in the countries listed below.

Ingredient matches for Biotonus

Mosapride

Mosapride is reported as an ingredient of Biotonus in the following countries:

Peru

International Drug Name Search

Riomet

Riomet is a brand name of metformin, approved by the FDA in the following formulation(s):

RIOMET (metformin hydrochloride - solution; oral)

Manufacturer: RANBAXY

Approval date: September 11, 2003

Strength(s): 500MG/5ML ^[RLD]

Has a generic version of Riomet been approved?

No. There is currently no therapeutically equivalent version of Riomet available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Riomet. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Liquid formulation of metformin
Patent 6,890,957
Issued: May 10, 2005
Inventor(s): Chandran; Ravi & Gogia; Ashish
Assignee(s): Ranbaxy Laboratories Limited
The present invention is directed to a liquid formulation of metformin or its pharmaceutically acceptable salts thereof. The liquid pharmaceutical composition comprises a therapeutically effective amount of metformin or its pharmaceutically acceptable salt, in a liquid carrier, which may also include a sweetener that does not increase the blood glucose level of a subject after ingestion thereof. In one embodiment, it may also include alkyl hydroxyethylcellulose, and/or a polyhydroxy alcohol. In another embodiment, the carrier may contain a sweetener, mineral acid, and bicarbonate salt maintained at a pH of 4.0 to 9.0. It is useful for treating hyperglycemia and diabetes.
Patent expiration dates:
- September 14, 2023
  ✓
  Drug product

Ingredient matches for Raciper-D

Domperidone

Domperidone is reported as an ingredient of Raciper-D in the following countries:

India

Esomeprazole

Esomeprazole magnesium, trihydrate (a derivative of Esomeprazole) is reported as an ingredient of Raciper-D in the following countries:

India

International Drug Name Search

Suprenza

Suprenza is a brand name of phentermine, approved by the FDA in the following formulation(s):

SUPRENZA (phentermine hydrochloride - tablet, orally disintegrating; oral)

Manufacturer: CITIUS PHARMS

Approval date: June 13, 2011

Strength(s): 15MG, 30MG ^[RLD]

Has a generic version of Suprenza been approved?

No. There is currently no therapeutically equivalent version of Suprenza available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Suprenza. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Process for the preparation of a granulate suitable to the preparation of rapidly disintegrable mouth-soluble tablets and compositions obtained thereby
Patent 6,149,938
Issued: November 21, 2000
Inventor(s): Bonadeo; Daniele & Ciccarello; Franco & Pagano; Aberto
Assignee(s): Elan Pharma International Limited
A process for making a granulate composition suitable to the preparation of an oral solid form that can disintegrate rapidly inside the buccal cavity is provided as well as the granulate compositions and obtained.
Patent expiration dates:
- July 23, 2018
  ✓
  Drug product

Has a generic version of Cardene SR been approved?

No. There is currently no therapeutically equivalent version of Cardene SR available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cardene SR. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Cardene SR.

Has a generic version of Requip been approved?

Yes. The following products are equivalent to Requip:

ropinirole hydrochloride tablet; oral

Manufacturer: ALEMBIC LTD

Approval date: March 24, 2010

Strength(s): EQ 0.25MG BASE ^[AB], EQ 0.5MG BASE ^[AB], EQ 1MG BASE ^[AB], EQ 2MG BASE ^[AB], EQ 3MG BASE ^[AB], EQ 4MG BASE ^[AB], EQ 5MG BASE ^[AB]

Manufacturer: APOTEX

Approval date: February 7, 2012

Strength(s): EQ 0.25MG BASE ^[AB], EQ 0.5MG BASE ^[AB], EQ 1MG BASE ^[AB], EQ 2MG BASE ^[AB], EQ 3MG BASE ^[AB], EQ 4MG BASE ^[AB], EQ 5MG BASE ^[AB]

Manufacturer: COREPHARMA

Approval date: May 20, 2008

Strength(s): EQ 0.25MG BASE ^[AB], EQ 0.5MG BASE ^[AB], EQ 1MG BASE ^[AB], EQ 2MG BASE ^[AB], EQ 3MG BASE ^[AB], EQ 4MG BASE ^[AB], EQ 5MG BASE ^[AB]

Manufacturer: GLENMARK GENERICS

Approval date: February 25, 2010

Strength(s): EQ 0.25MG BASE ^[AB], EQ 0.5MG BASE ^[AB], EQ 1MG BASE ^[AB], EQ 2MG BASE ^[AB], EQ 3MG BASE ^[AB], EQ 4MG BASE ^[AB], EQ 5MG BASE ^[AB]

Manufacturer: MYLAN

Approval date: May 5, 2008

Strength(s): EQ 0.25MG BASE ^[AB], EQ 0.5MG BASE ^[AB], EQ 1MG BASE ^[AB], EQ 2MG BASE ^[AB], EQ 3MG BASE ^[AB], EQ 4MG BASE ^[AB]

Manufacturer: MYLAN

Approval date: May 19, 2008

Strength(s): EQ 5MG BASE ^[AB]

Manufacturer: PRINSTON INC

Approval date: May 5, 2008

Strength(s): EQ 0.25MG BASE ^[AB], EQ 0.5MG BASE ^[AB], EQ 1MG BASE ^[AB], EQ 2MG BASE ^[AB], EQ 3MG BASE ^[AB], EQ 4MG BASE ^[AB]

Manufacturer: PRINSTON INC

Approval date: July 11, 2008

Strength(s): EQ 5MG BASE ^[AB]

Manufacturer: ROXANE

Approval date: May 5, 2008

Strength(s): EQ 0.25MG BASE ^[AB], EQ 0.5MG BASE ^[AB], EQ 1MG BASE ^[AB], EQ 2MG BASE ^[AB], EQ 3MG BASE ^[AB], EQ 4MG BASE ^[AB]

Manufacturer: ROXANE

Approval date: May 19, 2008

Strength(s): EQ 5MG BASE ^[AB]

Manufacturer: TEVA

Approval date: May 5, 2008

Strength(s): EQ 0.25MG BASE ^[AB], EQ 0.5MG BASE ^[AB], EQ 1MG BASE ^[AB], EQ 2MG BASE ^[AB], EQ 3MG BASE ^[AB], EQ 4MG BASE ^[AB]

Manufacturer: TEVA

Approval date: May 19, 2008

Strength(s): EQ 5MG BASE ^[AB]

Manufacturer: WOCKHARDT

Approval date: May 29, 2008

Strength(s): EQ 0.25MG BASE ^[AB], EQ 0.5MG BASE ^[AB], EQ 1MG BASE ^[AB], EQ 2MG BASE ^[AB], EQ 3MG BASE ^[AB], EQ 4MG BASE ^[AB], EQ 5MG BASE ^[AB]

Manufacturer: ZYDUS PHARMS USA INC

Approval date: June 1, 2009

Strength(s): EQ 0.25MG BASE ^[AB], EQ 0.5MG BASE ^[AB], EQ 1MG BASE ^[AB], EQ 2MG BASE ^[AB], EQ 3MG BASE ^[AB], EQ 4MG BASE ^[AB], EQ 5MG BASE ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Requip. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Requip.

Ingredient matches for Restavit

Doxylamine

Doxylamine succinate (a derivative of Doxylamine) is reported as an ingredient of Restavit in the following countries:

Australia

International Drug Name Search

Samsca

Samsca is a brand name of tolvaptan, approved by the FDA in the following formulation(s):

SAMSCA (tolvaptan - tablet; oral)

Manufacturer: OTSUKA AMERICA PHARM

Approval date: May 19, 2009

Strength(s): 15MG, 30MG ^[RLD]

Has a generic version of Samsca been approved?

No. There is currently no therapeutically equivalent version of Samsca available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Samsca. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Benzoheterocyclic compounds
Patent 5,753,677
Issued: May 19, 1998
Inventor(s): Ogawa; Hidenori & Miyamoto; Hisashi & Kondo; Kazumi & Yamashita; Hiroshi & Nakaya; Kenji & Komatsu; Hajime & Tanaka; Michinori & Kora; Shinya & Tominaga; Michiaki & Yabuuchi; Yoichi
Assignee(s): Otsuka Pharmaceutical Co., Ltd.
Novel benzoheterocyclic compounds of the formula: ##STR1## which have excellent vasopressin antagonistic activities and are useful as vasodilator, hypotensive agent, water diuretics, platelet agglutination inhibitor, and a vasopressin antagonistic composition containing the compound as the active ingredient.
Patent expiration dates:
- May 19, 2015
  ✓
  Patent use: METHOD OF TREATING HYPONATREMIA

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

Exclusivity expiration dates:
- May 19, 2014 - NEW CHEMICAL ENTITY

Has a generic version of Carnitor been approved?

A generic version of Carnitor has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Carnitor and have been approved by the FDA:

levocarnitine injectable; injection

Manufacturer: BEDFORD

Approval date: March 29, 2001

Strength(s): 200MG/ML ^[AP]

Manufacturer: LUITPOLD

Approval date: June 22, 2001

Strength(s): 200MG/ML ^[AP]

Manufacturer: TEVA PARENTERAL

Approval date: March 29, 2001

Strength(s): 200MG/ML ^[AP]

levocarnitine solution; oral

Manufacturer: HI TECH PHARMA

Approval date: October 25, 2007

Strength(s): 1GM/10ML ^[AA]

Manufacturer: LYNE

Approval date: August 10, 2004

Strength(s): 1GM/10ML ^[AA]

levocarnitine tablet; oral

Manufacturer: COREPHARMA

Approval date: September 20, 2004

Strength(s): 330MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Carnitor. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Treating chronic uremic patients undergoing periodical dialysis
Patent 6,335,369
Issued: January 1, 2002
Inventor(s): Claudio; Cavazza
Assignee(s): Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
Chronic uremic patients undergoing periodical dialysis are treated with carnitine or one of its salts to prevent or treat carnitine deficiency in patients with end stage renal disease. An effective dose of carnitine, preferably L-carnitine fumarate, is administered preferably intravenously into the venous return line after each dialysis session.
Patent expiration dates:
- January 18, 2021
  ✓
  Patent use: USE OF LEVOCARITINE IN PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS

Treating chronic uremic patients undergoing periodical dialysis
Patent 6,429,230
Issued: August 6, 2002
Inventor(s): Claudio; Cavazza
Assignee(s): Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
The method for the treatment chronic uremic patients undergoing periodical dialysis is useful for preventing and/or treating carnitine deficiency in patients with end stage renal disease who are undergoing dialysis. The method according to the present invention comprises administering an effective dose of carnitine intravenously into the venous return line after each dialysis session.
Patent expiration dates:
- January 18, 2021
  ✓
  Patent use: USE OF LEVOCARITINE IN PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS

Treating chronic uremic patients undergoing periodic dialysis
Patent 6,696,493
Issued: February 24, 2004
Inventor(s): Claudio; Cavazza
Assignee(s): Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
The method for the treatment of chronic uremic patients undergoing periodical dialysis is useful for preventing and/or treating carnitine deficiency in patients with end stage renal disease who are undergoing dialysis. The method according to the present invention comprises administering an effective dose of carnitine intravenously into the venous return line after each dialysis session.
Patent expiration dates:
- January 18, 2021
  ✓
  Patent use: USE OF LEVOCARITINE IN PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS

Ingredient matches for Visine

Carbomer

Carbomer is reported as an ingredient of Visine in the following countries:

Germany

Oxymetazoline

Oxymetazoline hydrochloride (a derivative of Oxymetazoline) is reported as an ingredient of Visine in the following countries:

Argentina

Povidone

Povidone is reported as an ingredient of Visine in the following countries:

Germany

Tetryzoline

Tetryzoline hydrochloride (a derivative of Tetryzoline) is reported as an ingredient of Visine in the following countries:

Australia

Belgium

Chile

Croatia (Hrvatska)

Czech Republic

Egypt

Estonia

Ethiopia

Finland

Georgia

Ghana

Hong Kong

Hungary

India

Israel

Kenya

Latvia

Liberia

Lithuania

Malawi

New Zealand

Nigeria

Philippines

Poland

Portugal

Romania

Russian Federation

Serbia

Sierra Leone

Singapore

Slovakia

Sudan

Thailand

Turkey

United States

Vietnam

International Drug Name Search

GNP Pediatric Electrolyte Strips

Pronunciation: e-LEK-tro-lite
Generic Name: Electrolyte
Brand Name: GNP Pediatric Electrolyte

GNP Pediatric Electrolyte Strips are used for:

Treating or preventing electrolyte loss caused by vomiting or diarrhea. It may also be used for other conditions as determined by your doctor.

GNP Pediatric Electrolyte Strips are an electrolyte combination. It works by replacing electrolytes (eg, sodium, potassium) that may be lost due to vomiting or diarrhea.

Do NOT use GNP Pediatric Electrolyte Strips if:

you are allergic to any ingredient in GNP Pediatric Electrolyte Strips

you have high blood sodium or potassium levels

Contact your doctor or health care provider right away if any of these apply to you.

Before using GNP Pediatric Electrolyte Strips:

Some medical conditions may interact with GNP Pediatric Electrolyte Strips. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

if you are pregnant, planning to become pregnant, or are breast-feeding

if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

if you have allergies to medicines, foods, or other substances

if you have heart failure, fluid retention (eg, swelling of the hands, ankles, or feet), intestinal holes or punctures, difficulty urinating, kidney problems, or unexplained rectal bleeding

if you have severe or persistent vomiting, severe diarrhea, or if you are dehydrated

Some MEDICINES MAY INTERACT with GNP Pediatric Electrolyte Strips. However, no specific interactions with GNP Pediatric Electrolyte Strips are known at this time.

Ask your health care provider if GNP Pediatric Electrolyte Strips may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use GNP Pediatric Electrolyte Strips:

Use GNP Pediatric Electrolyte Strips as directed by your doctor. Check the label on the medicine for exact dosing instructions.

Take GNP Pediatric Electrolyte Strips by mouth with or without food.

Do not mix GNP Pediatric Electrolyte Strips with water or any other liquid.

Place GNP Pediatric Electrolyte Strips in the mouth on the tongue or cheek and allow it to dissolve.

Drinking extra fluids while you are taking GNP Pediatric Electrolyte Strips are recommended. Check with your doctor for instructions.

If you miss a dose of GNP Pediatric Electrolyte Strips, take it as soon as you remember. Continue to take it as directed by your doctor or on the package label.

Ask your health care provider any questions you may have about how to use GNP Pediatric Electrolyte Strips.

Important safety information:

If vomiting, fever, stomach pain or bloating, or diarrhea that lasts longer than 24 hours occurs, check with your doctor.

Do not use GNP Pediatric Electrolyte Strips in CHILDREN younger than 2 years old without first checking with the child's doctor.

PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using GNP Pediatric Electrolyte Strips while you are pregnant. It is not known if GNP Pediatric Electrolyte Strips are found in breast milk. If you are or will be breast-feeding while you use GNP Pediatric Electrolyte Strips, check with your doctor. Discuss any possible risks to your baby.

Possible side effects of GNP Pediatric Electrolyte Strips:

All medicines may cause side effects, but many people have no, or minor, side effects. When used in small doses, no COMMON side effects have been reported with this product. Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue).

If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

See also: GNP Pediatric Electrolyte side effects (in more detail)

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately.

Proper storage of GNP Pediatric Electrolyte Strips:

Store GNP Pediatric Electrolyte Strips at room temperature, between 68 and 77 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep GNP Pediatric Electrolyte Strips out of the reach of children and away from pets.

General information:

If you have any questions about GNP Pediatric Electrolyte Strips, please talk with your doctor, pharmacist, or other health care provider.

GNP Pediatric Electrolyte Strips are to be used only by the patient for whom it is prescribed. Do not share it with other people.

If your symptoms do not improve or if they become worse, check with your doctor.

Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about GNP Pediatric Electrolyte Strips. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Issue Date: February 1, 2012

Database Edition 12.1.1.002

Lovenox

Lovenox is a brand name of enoxaparin, approved by the FDA in the following formulation(s):

LOVENOX (enoxaparin sodium - injectable; intravenous, subcutaneous)

Manufacturer: SANOFI AVENTIS US

Approval date: January 23, 2003

Strength(s): 300MG/3ML (100MG/ML) ^[AB]

Has a generic version of Lovenox been approved?

A generic version of Lovenox has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Lovenox and have been approved by the FDA:

enoxaparin sodium injectable; intravenous, subcutaneous

Manufacturer: SANDOZ INC

Approval date: November 28, 2011

Strength(s): 300MG/3ML (100MG/ML) ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Lovenox. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Mixtures of particular LMW heparinic polysaccharides for the prophylaxis/treatment of acute thrombotic events
Patent 5,389,618
Issued: February 14, 1995
Inventor(s): Debrie; Roger
Assignee(s): Rhone-Poulenc Rorer S.A.
Heterogeneous intimate admixtures of sulfated heparinic polysaccharides, well suited for the prophylaxis/treatment of acute thrombotic episodes in a human patient, comprise immixture of sulfated polysaccharides having a weight average molecular weight less than that of heparin and which include from 9% to 20% of polysaccharide chains having a molecular weight less than 2,000 daltons and from 5% to 20% of polysaccharide chains having a molecular weight greater than 8,000 daltons, the ratio between the weight average molecular weight and the number average molecular weight thereof ranging from 1.3 to 1.6.
Patent expiration dates:
- February 14, 2012
  ✓
  Patent use: METHOD FOR THE PREVENTION AND/OR TREATMENT OF THROMBOTIC EPISODES, SUCH AS MYOCARDIAL INFARCTION, IN A HUMAN PATIENT AND METHOD FOR THE PREVENTION OF VENOUS THROMBOSIS IN A POSTOPERATIVE HUMAN PATIENT
  ✓
  Drug substance
  ✓
  Drug product

Mixtures of particular LMW heparinic polysaccharides for the prophylaxis/treatment of acute thrombotic events
Patent RE38743
Issued: June 14, 2005
Inventor(s): Debrie; Roger
Assignee(s): Aventis Pharma S.A.
Heterogeneous intimate admixtures of sulfated heparinic polysaccharides, well suited for the prophylaxis/treatment of acute thrombotic episodes in a human patient, comprise immixture of sulfated polysaccharides having a weight average molecular weight less than that of heparin and which include from 9% to 20% of polysaccharide chains having a molecular weight less than 2,000 daltons and from 5% to 20% of polysaccharide chains having a molecular weight greater than 8,000 daltons, the ratio between the weight average molecular weight and the number average molecular weight thereof ranging from 1.3 to 1.6.
Patent expiration dates:
- February 14, 2012
  ✓
  Patent use: METHOD FOR THE PREVENTION AND/OR TREATMENT OF THROMBOTIC EPISODES, SUCH AS MYOCARDIAL INFARCTION, IN A HUMAN PATIENT AND METHOD FOR THE PREVENTION OF VENOUS THROMBOSIS IN A POSTOPERATIVE HUMAN PATIENT
  ✓
  Drug substance
  ✓
  Drug product

Has a generic version of Ridaura been approved?

No. There is currently no therapeutically equivalent version of Ridaura available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ridaura. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Ridaura.

Has a generic version of Canasa been approved?

No. There is currently no therapeutically equivalent version of Canasa available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Canasa. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Canasa.

Has a generic version of Ritalin been approved?

Yes. The following products are equivalent to Ritalin:

methylphenidate hydrochloride tablet; oral

Manufacturer: MALLINCKRODT

Approval date: November 27, 1998

Strength(s): 10MG ^[AB], 20MG ^[AB], 5MG ^[AB]

Manufacturer: UCB INC

Approved Prior to Jan 1, 1982

Strength(s): 10MG ^[AB], 20MG ^[AB], 5MG ^[AB]

Manufacturer: WATSON LABS

Approval date: August 29, 1997

Strength(s): 10MG ^[AB], 20MG ^[AB], 5MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ritalin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Ritalin.

Has a generic version of Sabril been approved?

No. There is currently no therapeutically equivalent version of Sabril available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Sabril. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Sabril.

Related Exclusivities

Exclusivity expiration dates:
- August 21, 2014 - NEW CHEMICAL ENTITY
- August 21, 2016 - ORPHAN DRUG EXCLUSIVITY

What is Perdiem Fiber Caplet (polycarbophil)?

Polycarbophil is a bulk-forming laxative that increases the amount of water in your stools to help make them softer and easier to pass.

Polycarbophil is used to treat constipation and to help maintain regular bowel movements.

Polycarbophil may also be used in some cases to treat diarrhea or irritable bowel syndrome.

Polycarbophil may also be used for other purposes not listed in this medication guide.

What is the most important information I should know about Perdiem Fiber Caplet (polycarbophil)?

You should not use this medication if you are allergic to polycarbophil or to mineral oil, sodium laurel sulfate, or povidone (such as Betadine).

Before using polycarbophil, tell your doctor if you are allergic to any drugs, or if you have trouble swallowing, a blockage in your intestines, stomach pain with nausea or vomiting, a history of bleeding from your rectum, or a sudden change in your bowel habits that has lasted for 2 weeks or longer.

Ask your doctor before taking polycarbophil if you are pregnant or breast-feeding. The polycarbophil tablet may expand in your throat and cause you to choke if you do not use enough liquid to help swallow the pill. Be sure to drink a full 8-ounce glass of water or other liquid while swallowing the regular tablet or after chewing the chewable tablet.

Polycarbophil is usually taken up to 4 times per day. Do not take more than recommended by your doctor or listed on the medicine label.

Polycarbophil should cause you to have a bowel movement within 12 to 72 hours.

Do not take polycarbophil for longer than 7 days unless your doctor tells you to.

What should I discuss with my health care provider before taking Perdiem Fiber Caplet (polycarbophil)?

You should not use this medication if you are allergic to polycarbophil or to mineral oil, sodium laurel sulfate, or povidone (such as Betadine).

Before using polycarbophil, tell your doctor if you are allergic to any drugs, or if you have:

trouble swallowing;

a blockage in your intestines;

stomach pain with nausea or vomiting;

a history of bleeding from your rectum; or

a sudden change in your bowel habits that has lasted for 2 weeks or longer.

If you have any of these conditions, you may not be able to take polycarbophil, or you may need a dose adjustment or special tests during treatment.

Ask your doctor before taking polycarbophil if you are pregnant or breast-feeding.

Some forms of polycarbophil may contain phenylalanine. Talk to your doctor before using this medication if you have phenylketonuria (PKU).

Do not give this medicine to a young child without the advice of a doctor.

How should I take Perdiem Fiber Caplet (polycarbophil)?

Use this medication exactly as directed on the label, or as prescribed by your doctor. Do not use it in larger amounts or for longer than recommended.

Take this medicine with a full glass (8 ounces) of water or other liquid. The tablet may expand in your throat and cause you to choke if you do not use enough liquid to help swallow the pill. Unless you need to restrict your fluid intake, drink plenty of fluids each day while you are taking polycarbophil.

The chewable tablet must be chewed before your swallow it.

Older adults may be more likely to choke while taking this medication. Be sure to drink a full glass of water while swallowing the regular tablet, or after chewing the chewable tablet.

Polycarbophil is usually taken up to 4 times per day. Do not take more of this medicine than recommended by your doctor or printed on the medicine label.

Polycarbophil should cause you to have a bowel movement within 12 to 72 hours. Call your doctor if your constipation does not improve after 3 days of taking this medication.

Do not take polycarbophil for longer than 7 days unless your doctor tells you to. Overuse of a laxative may cause damage to the nerves, muscles, or tissues in your intestines. Store polycarbophil at room temperature away from moisture and heat.

What happens if I miss a dose?

Since polycarbophil is usually taken as needed, you will not be on a long-term dosing schedule. If you are taking the medication daily for up to 7 days, take the missed dose as soon as you remember. If it is almost time for your next dose, wait until then to take the medicine and skip the missed dose. Do not take extra medicine to make up the missed dose.

What happens if I overdose?

Seek emergency medical attention if you think you have used too much of this medicine.

An overdose of polycarbophil is not likely to produce life-threatening side effects.

What should I avoid while taking Perdiem Fiber Caplet (polycarbophil)?

Avoid taking polycarbophil within 2 hours before or after you take any other medications. A laxative can make it harder for your body to absorb other medicines.

Perdiem Fiber Caplet (polycarbophil) side effects

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Stop using polycarbophil and call your doctor at once if you have a serious side effect such as:

vomiting;

choking on the tablet;

trouble swallowing;

chest pain; or

rectal bleeding.

Less serious side effects may include:

mild stomach pain;

bloating; or

gas.

This is not a complete list of side effects and others may occur. Tell your doctor about any unusual or bothersome side effect. You may report side effects to FDA at 1-800-FDA-1088.

What other drugs will affect Perdiem Fiber Caplet (polycarbophil)?

There may be other drugs that can interact with polycarbophil. Tell your doctor about all your prescription and over-the-counter medications, vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start a new medication without telling your doctor.

More Perdiem Fiber Caplet resources

Perdiem Fiber Caplet Drug Interactions
Perdiem Fiber Caplet Support Group
0 Reviews for Perdiem Fiber Caplet - Add your own review/rating

Compare Perdiem Fiber Caplet with other medications

Constipation

Where can I get more information?

Your pharmacist can provide more information about polycarbophil.

CellCept

CellCept is a brand name of mycophenolate mofetil, approved by the FDA in the following formulation(s):

CELLCEPT (mycophenolate mofetil - capsule; oral)

Manufacturer: ROCHE PALO

Approval date: May 3, 1995

Strength(s): 250MG ^[RLD]^[AB]

CELLCEPT (mycophenolate mofetil - suspension; oral)

Manufacturer: ROCHE PALO

Approval date: October 1, 1998

Strength(s): 200MG/ML ^[RLD]

CELLCEPT (mycophenolate mofetil - tablet; oral)

Manufacturer: ROCHE PALO

Approval date: June 19, 1997

Strength(s): 500MG ^[RLD]^[AB]

CELLCEPT (mycophenolate mofetil hydrochloride - injectable; injection)

Manufacturer: ROCHE PALO

Approval date: August 12, 1998

Strength(s): 500MG/VIAL ^[RLD]

Has a generic version of CellCept been approved?

A generic version of CellCept has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to CellCept and have been approved by the FDA:

mycophenolate mofetil capsule; oral

Manufacturer: ACCORD HLTHCARE INC

Approval date: May 4, 2009

Strength(s): 250MG ^[AB]

Manufacturer: APOTEX CORP

Approval date: April 22, 2009

Strength(s): 250MG ^[AB]

Manufacturer: DR REDDYS LABS LTD

Approval date: October 27, 2011

Strength(s): 250MG ^[AB]

Manufacturer: ENDO PHARMS

Approval date: December 22, 2009

Strength(s): 250MG ^[AB]

Manufacturer: MYLAN

Approval date: May 4, 2009

Strength(s): 250MG ^[AB]

Manufacturer: ROXANE

Approval date: July 29, 2008

Strength(s): 250MG ^[AB]

Manufacturer: SANDOZ

Approval date: October 15, 2008

Strength(s): 250MG ^[AB]

Manufacturer: STRIDES ARCOLAB LTD

Approval date: June 10, 2010

Strength(s): 250MG ^[AB]

Manufacturer: TEVA PHARMS

Approval date: May 6, 2009

Strength(s): 250MG ^[AB]

Manufacturer: ZYDUS PHARMS USA INC

Approval date: May 4, 2009

Strength(s): 250MG ^[AB]

mycophenolate mofetil tablet; oral

Manufacturer: ACCORD HLTHCARE

Approval date: May 4, 2009

Strength(s): 500MG ^[AB]

Manufacturer: ALKEM LABS LTD

Approval date: November 4, 2011

Strength(s): 500MG ^[AB]

Manufacturer: APOTEX

Approval date: April 22, 2009

Strength(s): 500MG ^[AB]

Manufacturer: ENDO PHARMS

Approval date: July 16, 2010

Strength(s): 500MG ^[AB]

Manufacturer: MYLAN

Approval date: May 4, 2009

Strength(s): 500MG ^[AB]

Manufacturer: ROXANE

Approval date: July 29, 2008

Strength(s): 500MG ^[AB]

Manufacturer: SANDOZ

Approval date: October 15, 2008

Strength(s): 500MG ^[AB]

Manufacturer: STRIDES ARCOLAB LTD

Approval date: June 10, 2010

Strength(s): 500MG ^[AB]

Manufacturer: TEVA PHARMS

Approval date: May 4, 2009

Strength(s): 500MG ^[AB]

Manufacturer: ZYDUS PHARMS USA INC

Approval date: May 4, 2009

Strength(s): 500MG ^[AB]

Note: No generic formulation of the following products are available.

mycophenolate mofetil - suspension; oral

mycophenolate mofetil hydrochloride - injectable; injection

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of CellCept. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Crystalline anhydrous mycophenolate mofetil and intravenous formulation thereof
Patent 5,543,408
Issued: August 6, 1996
Inventor(s): Fu; Roger C. & Leung; De-Mei & Fleitman; Jeffrey S. & Rizzolio; Michele C. & Miksztal; Andrew R.
Assignee(s): Syntex (U.S.A.) Inc.
The crystalline anhydrous salt formed by complexing mycophenolate mofetil with an anion selected from the group chloride, sulfate, phosphate and acetate (in particular the hydrochloride salt), and pharmaceutical compositions, intravenous formulations and a kit thereof, and associated methods of treatment.
Patent expiration dates:
- September 15, 2013
  ✓
  Drug product

Mycophenolate mofetil high dose oral suspensions
Patent 5,688,529
Issued: November 18, 1997
Inventor(s): Lidgate; Deborah Marilyn & Wang-Kessler; Li-hua & Joshi; Bindu & Hegde; Sayee Gojanan & Gu; Leo
Assignee(s): Syntex (U.S.A) Inc.
High dose, dry granulations or powder blends and aqueous oral suspensions of mycophenolate mofetil or mycophenolic acid, contain: active compound (7.5-30%), suspending/viscosity agent, sweetener, flavor, buffer (to a pH of 5-7.5), and optionally contain flavor enhancer, wetting agent, antimicrobial agent and color.
Patent expiration dates:
- November 18, 2014
  ✓
  Drug product

Thursday, September 29, 2016

Ingredient matches for Spanil

ACANYA (benzoyl peroxide; clindamycin phosphate - gel; topical)

Has a generic version of Acanya been approved?

Related Patents

See also...

Wednesday, September 28, 2016

SINEMET (carbidopa; levodopa - tablet; oral)

Has a generic version of Sinemet been approved?

CARBIDOPA AND LEVODOPA (carbidopa; levodopa tablet; oral)

Related Patents

See also...

SINEMET CR (carbidopa; levodopa - tablet, extended release; oral)

Has a generic version of Sinemet CR been approved?

CARBIDOPA AND LEVODOPA (carbidopa; levodopa tablet, extended release; oral)

Related Patents

See also...

SOLODYN (minocycline hydrochloride - tablet, extended release; oral)

Has a generic version of Solodyn been approved?

minocycline hydrochloride tablet, extended release; oral

Related Patents

See also...

Ingredient matches for Procid

Commonly used brand name(s)

Uses For Optison

Before Using Optison

Allergies

Pediatric

Geriatric

Pregnancy

Breast Feeding

Interactions with Medicines

Interactions with Food/Tobacco/Alcohol

Other Medical Problems

Proper Use of Optison

Dosing

Precautions While Using Optison

Optison Side Effects

More Optison resources

Ingredient matches for Biotonus

RIOMET (metformin hydrochloride - solution; oral)

Has a generic version of Riomet been approved?

Related Patents

See also...

Ingredient matches for Raciper-D

SUPRENZA (phentermine hydrochloride - tablet, orally disintegrating; oral)

Has a generic version of Suprenza been approved?

Related Patents

See also...

CARDENE SR (nicardipine hydrochloride - capsule, extended release; oral)

Has a generic version of Cardene SR been approved?

Related Patents

See also...

REQUIP (ropinirole hydrochloride - tablet; oral)

Has a generic version of Requip been approved?

ropinirole hydrochloride tablet; oral

Related Patents

See also...

Ingredient matches for Restavit

SAMSCA (tolvaptan - tablet; oral)

Has a generic version of Samsca been approved?

Related Patents

Related Exclusivities

See also...

CARNITOR (levocarnitine - injectable; injection)

CARNITOR (levocarnitine - solution; oral)

CARNITOR (levocarnitine - tablet; oral)

Has a generic version of Carnitor been approved?

levocarnitine injectable; injection

levocarnitine solution; oral

levocarnitine tablet; oral

Related Patents

See also...

Ingredient matches for Visine

GNP Pediatric Electrolyte Strips are used for:

Do NOT use GNP Pediatric Electrolyte Strips if:

Before using GNP Pediatric Electrolyte Strips:

How to use GNP Pediatric Electrolyte Strips:

Important safety information:

Possible side effects of GNP Pediatric Electrolyte Strips: